Cartesian Therapeutics, Inc. — Director's Dealing 2024

Nov 19, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Cartesian Therapeutics, Inc. (RNAC)
CIK: 0001453687
Period of Report: 2024-11-14

Reporting Person: SPRINGER TIMOTHY A (Director, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-11-14	Common Stock	P	74157	$16.1916	Acquired	8097923	Direct
2024-11-14	Common Stock	P	22242	$16.9695	Acquired	8120165	Direct
2024-11-15	Common Stock	P	277246	$17.0938	Acquired	8397411	Direct
2024-11-18	Common Stock	P	38114	$17.9579	Acquired	8435525	Direct
2024-11-18	Common Stock	P	20181	$18.4201	Acquired	8455706	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	330695	Indirect
Common Stock	529798	Indirect

Footnotes

F1: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $15.65 to $16.60. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

F2: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $16.71 to $17.00. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

F3: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $16.61 to $17.25. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

F4: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $17.32 to $18.315. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

F5: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $18.32 to $18.50. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

F6: Held by TAS Partners LLC. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any.